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ABSTRACT Melioidosis is a neglected tropical disease caused by the bacterium
Burkholderia pseudomallei. The bacterium is intrinsically resistant to various antibiot-
ics, and melioidosis is therefore difficult to treat successfully without a relapse in
infection. B. pseudomallei is an intracellular pathogen and therefore, to eradicate the
infection, antimicrobials must be able to access bacteria in an intracellular niche.
This study assessed the ability of a panel of monoclonal antibodies (MAbs) to opson-
ize Burkholderia species and determine the effect that each antibody has on bacterial
virulence in vitro. Murine macrophage infection assays demonstrated that monoclo-
nal antibodies against the capsule of B. pseudomallei are opsonizing. Furthermore,
one of these monoclonal antibodies reduced bacterial actin tail formation in our in
vitro assays, indicating that antibodies could reduce the intracellular spread of
Burkholderia thailandensis. The data presented in this paper demonstrate that mono-
clonal antibodies are opsonizing and can decrease bacterial actin tail formation, thus
decreasing their intracellular spread. These data have informed selection of an anti-
body for development of an antibody-antibiotic conjugate (AAC) for melioidosis.
IMPORTANCE Melioidosis is difficult to treat successfully due to the causal bacterium
being resistant to many classes of antibiotics, therefore limiting available therapeutic
options. New and improved therapies are urgently required to treat this disease.
Here, we have investigated the potential of monoclonal antibodies to target this in-
tracellular pathogen. We have demonstrated that monoclonal antibodies can target
the bacterium, increase uptake into macrophages, and reduce actin tail formation
required by the bacterium for spread between cells. Through targeting the bacte-
rium with antibodies, we hope to disarm the pathogen, reducing the spread of infec-
tion. Ultimately, we aim to use an opsonizing antibody to deliver antibiotics intracell-
ularly by developing an antibody-antibiotic conjugate therapeutic for melioidosis.
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Melioidosis is a potentially fatal neglected tropical disease caused by the Gram-nega-tive bacterium Burkholderia pseudomallei. It has been estimated that 165,000 cases of
melioidosis occur worldwide each year, with up to 89,000 deaths (1). Melioidosis is often
misdiagnosed due to the wide variety of symptoms associated with the disease (2, 3). Even
with successful diagnosis and treatment, studies have shown relapse rates of between 13
and 23% in survivors (4–7), with the majority of cases occurring within 12 months of initial
therapy. Due to the complex antibiotic therapy, rates of relapse and the prevalence of anti-
microbial resistance, it is clear that new therapeutic approaches are required to aid in the
treatment of melioidosis. Monoclonal antibody (MAb) therapies have been in development
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in the oncology field for many years (8), with research and development into antibody-
based therapeutics for infectious diseases accelerating in recent years (9).
B. pseudomallei is well equipped to evade killing by the immune system. One aspect
to this is its ability to reside within host cells, therefore avoiding detection and denying
access to humoral defenses. The bacterium has a large genome of 7.2 Mb, which is split
between two chromosomes. These chromosomes encode virulence factors such as
capsular polysaccharide (CPS), lipopolysaccharide (LPS), adhesins, flagella, and secre-
tory systems, of which the type three and type six secretory systems are required for
optimum intracellular survival and virulence (10–14).
B. pseudomallei can infect a variety of phagocytic and nonphagocytic cells. B. pseu-
domallei adhesins, such as BoaA and BoaB, are important factors for adhesion to non-
phagocytic cells (14). Following phagocytosis into macrophage cells, B. pseudomallei
can escape endocytic vacuoles using the type three secretory system (T3SS) apparatus
(15, 16). Once in the cytosol, the bacteria move via actin-based motility; this process is
a bacterially mediated process that involves the bacteria recruiting host actin from the
cytoskeleton in the form of G actin, when is then assembled into F actin by mimicking
host cell nucleation-promoting factors (17–21). In B. pseudomallei and Burkholderia
thailandensis, this process is driven by the BimA gene. Although the type VI secretion
systems of B. thailandensis and B. pseudomallei are responsible for the cellular fusion,
the motility of the bacterium is an important aspect of mobility to facilitate spread
(18). Actin-based motility is not unique to B. thailandensis, B. pseudomallei, and B. mal-
lei; for example, bacteria from the Shigella and Listeria genus can also utilize actin for
intracellular motility (22, 23). It is thought that actin-based motility leads to multi-
nucleated giant cell (MNGC) formation via the force exhibited on the cell membrane
promoting contact with adjacent cells (24). For B. pseudomallei and B. thailandensis,
MNGC formation is an important aspect of cellular invasion that can be seen in both
phagocytic and nonphagocytic cells, where intracellular bacterial replication eventually
leads to cell damage and plaque formation (25). The ability of B. pseudomallei to sur-
vive intracellularly, thus avoiding some traditional antibiotic therapies, highlights the
importance of investigating novel antimicrobial therapies for melioidosis.
Burkholderia thailandensis shares many similarities to the hazard group 3 pathogen
B. pseudomallei, although B. thailandensis is rarely pathogenic to humans and is there-
fore a hazard group 2 organism. B. thailandensis E555 can be used as a surrogate for B.
pseudomallei, as the bacterium possesses a polysaccharide capsule identical to the
polysaccharide capsule of B. pseudomallei (26) and is virulent in macrophage cell cul-
ture infection assays. Techniques for analyzing intracellular bacteria within RAW 264.7
macrophages by CFU and imaging flow cytometry have been previously reported for
B. thailandensis (27). A range of anti-Burkholderia murine monoclonal antibodies devel-
oped and owned by the Defence Science and Technology Laboratory (Dstl) have previ-
ously been tested in vivo for protection against B. pseudomallei in mice (28), with the
capsule-specific antibodies demonstrating a level of protection.
In this study, we test a range of Burkholderia-specific monoclonal antibodies for
their abilities to interfere with B. pseudomallei and B. thailandensis in vitro infection
and, as such, their suitability for use as therapies for melioidosis. The aim is to investi-
gate opsonization and its effect on intracellular bacteria. These antibody data set the
foundations for the generation of a proof-of-principle antibody-antibiotic conjugate
(AAC) for melioidosis.
RESULTS
Monoclonal antibodies are opsonizing in a RAW 264.7 macrophage infection
assay. A RAW 264.7 macrophage infection assay was used to determine monoclonal
antibody opsonization. Opsonization was assessed by measuring bacterial uptake with
a viable count assay and imaging flow cytometry, initially using B. thailandensis E555.
Each MAb (Table 1) was added to B. thailandensis concentrations ranging from 0.1 ng 
ml21 to 1 mg  ml21 (anti-CPS MAbs 4VIH12, 3VIE5, and 4VA5) and from 10 ng  ml21 to
100 mg  ml21 (anti-LPS MAb CC6). Antibodies were incubated for 30 min with the B.
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thailandensis cells to allow binding prior to macrophage infection. Numbers of viable
bacteria (CFU/well) were determined by lysis of intact macrophage cells and enumera-
tion of the intracellular bacteria by serial dilution and culture on Luria agar plates.
Imaging flow cytometry of intact macrophage cells was used as an additional method
to determine antibody opsonization, together with confocal microscopy for high-defi-
nition imaging of intracellular bacterial infection.
Intracellular CFU enumeration experiments showed that each MAb analyzed was opso-
nizing toward B. thailandensis E555 in the RAW264.7 macrophage infection assay (Fig. 1A).
A statistical modeling approach was taken to analyze the data, where the logarithmic
transformation of dose was included as a covariate and the bacteria, antibody, and repli-
cate experiments were included as fixed factors and with all interactions. Each anti-CPS
MAb is opsonizing in a dose-dependent manner (P , 0.001) by increasing intracellular
CFU level by a greater than 1-log fold increase. An average CFU of 2.1  104 CFU  ml21 is
observed at 0.0001 mg  ml21 of anti-CPS MAb; this increases to 4  105 CFU  ml21 at an
anti-CPS MAb concentration of 0.1mg  ml21. In comparison, an anti-LPS antibody concen-
tration of 10 mg  ml21 or greater is required to achieve a similar level of intracellular CFU
increase. Modeling suggested differences between antibodies (P , 0.001) with a greater
concentration of the anti-LPS MAb CC6 required to achieve an increase in B. thailandensis
intracellular CFU compared to the anti-CPS MAbs 4VIH12, 3VIE5, and 4VA5 (P , 0.001, for
all Bonferroni’s posttests in which CC6 MAb was compared to each of the other MAbs).
All MAbs analyzed for opsonization by imaging flow cytometry showed a dose-de-
pendent ability to increase the percentage of cells infected with B. thailandensis (Fig.
1C). A similar modeling approach was taken as with the CFU data. Again, there was a
dose response for the antibodies (P , 0.001) and a clear difference between the anti-
CPS MAbs (P , 0.001) (4VIH12, 3VIE5, and 4VA5) and the anti-LPS MAb (CC6), mirroring
the result seen by intracellular CFU analysis (P , 0.001 for all Bonferroni’s posttests in
which CC6 MAb was compared to each of the other MAbs). Additionally, imaging flow
cytometry can be used to estimate the proportional extent of bacterial presence within
the cell by “spot counting” in the focal plane of each cell (see Fig. S1 in the supplemen-
tal material). Although the spot counting profiles (Fig. 1E) differ between MAbs and
bacterial strains, the data indicate an increase in the average number of intracellular
bacteria per cell when opsonized with MAb. The spot count analysis broadly demon-
strated the same conclusions as the CFU-associated data, demonstrating a dose effect
(P, 0.001; analysis of covariance [ANCOVA] for dose response).
The ability of monoclonal antibodies to opsonize B. pseudomallei K96243 is
comparable to ability to opsonize B. thailandensis E555. The MAb panel was
assessed to determine if the opsonization ability demonstrated for B. thailandensis
E555 can also be applied to the highly pathogenic (Advisory Committee on Dangerous
Pathogens, UK (ACDP, level III B. pseudomallei K96243 (Fig. 1B, D, and F). A red fluores-
cent protein (RFP)-expressing strain of B. pseudomallei K96243 was used to enable visu-
alization of the bacterium within macrophage cells by imaging flow cytometry.
Analysis of intracellular bacteria by CFU enumeration and imaging flow cytometry
showed that opsonization of B. pseudomallei K96243 by each MAb is comparable to
the data for that of B. thailandensis E555 (Fig. 1). These data were analyzed within the
modeling discussed in the previous section, alongside the B. thailandensis data. We
found overall levels of uptake were different when measuring CFU (P , 0.001) or flow
cytometry (P = 0.009). However, these differences did not seem to alter the role of
TABLE 1Monoclonal antibodies evaluated in this study
Antibody Targeta Isotype Species
4VIH12 Anti-CPS IgG2b Murine
3VIE5 Anti-CPS IgG2b Murine
4VA5 Anti-CPS IgG1 Murine
CC6 Anti-LPS IgG2a Murine
aCPS, capsular polysaccharide; LPS, lipopolysaccharide.
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antibody when measuring CFU (P , 0.810) or flow cytometry (P = 0.891). The conclu-
sions are therefore the same as those with B. thailandensis. Each antibody was opsoniz-
ing and significantly increased bacterial uptake with dose (P , 0.001; ANCOVA for
dose response); anti-CPS MAbs (4VIH12, 3VIE5, and 4VA5) outperformed the anti-LPS
FIG 1 Monoclonal antibody opsonization. Burkholderia thailandensis (left) and Burkholderia pseudomallei (right) were opsonized at a range of
concentrations of anti-capsular polysaccharide (CPS) monoclonal antibodies (MAbs) (4VIH12, 3VIE5, and 4VA5) and anti-lipopolysaccharide
(LPS) MAb (CC6; note higher concentrations). Intracellular bacteria within RAW 264.7 macrophages were analyzed ay 2 h postinfection by
CFU enumeration (A, B), imaging flow cytometry (C, D), and spot counts (E, F). For each concentration of MAb, replicates were performed
across two separate experimental days. Controls consisted of an isotype control antibody at the highest concentration. (A to D) Statistics for
bacteriology and cytometry. P , 0.001 (analysis of covariance [ANCOVA]) for MAb dose response); P , 0.001 for all Bonferroni’s posttests in
which CC6 MAb was compared to each of the other MAbs. (E, F) Statistics for spot counts. P , 0.001 (ANCOVA for MAb dose response).
Imaging flow cytometry gating and spot count analysis are shown in Fig. S1 in the supplemental material.
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MAb (CC6) in terms of opsonization ability (P , 0.001 for all Bonferroni’s posttests in
which CC6 MAb was compared to each of the other MAbs). Antibody opsonization data
were used to select an anti-CPS antibody for further analysis in cell infection assays. The
anti-CPS MAb 3VIE5 was selected because this MAb had previously been shown in other
studies to have favorable binding kinetics (data not shown).
Opsonized B. thailandensis bacteria have a reduction in actin tail formation
within RAW 264.7 macrophages. Confocal microscopy was used to visualize infection
of RAW 264.7 macrophage cells with B. thailandensis E555 enhanced green fluorescent
protein (eGFP) over 24 h. Actin tail staining using fluorescently labeled phalloidin
reveals actin tail formation by intracellular B. thailandensis E555 (Fig. 2).
An open-source computer program, Icy (29), was used to analyze confocal micros-
copy images by quantifying the intensity of GFP-B. thailandensis and the intensity of
red phalloidin-stained actin tails, generating a ratio between the two.
Plotting the ratio generated from the GFP and phalloidin fluorescence clearly dem-
onstrates a difference in actin tail formation between 3VIE5 MAb-opsonized B. thailan-
densis and nonopsonized B. thailandensis in RAW 264.7 macrophages (Fig. 3). The B.
thailandensis cells opsonized with the anti-capsule MAb 3VIE5 have a reduced intensity
of actin tail fluorescence compared to that of both the isotype control antibody and
the nonopsonized bacterial control (P, 0.001 and P, 0.0001, respectively, using anal-
ysis of variance [ANOVA]). It is interesting that the isotype control antibody also has a
reduced actin tail formation ratio compared to that of the nonopsonized control
(P , 0.01). Our theory to explain this observation is that the isotype control antibody is
causing nonspecific activation of the RAW macrophages through the interaction with
their Fc receptor, thus increasing their activation status. This, in turn, leads to compart-
mentalization of the bacterium, thereby suppressing bacterial actin tail formation.
Opsonization does not increase bacterial colocalization with LAMP-1-positive
phagolysosomes. The MAb 3VIE5 has demonstrated the ability to opsonize and
reduce actin tail formation in vitro. Although it is known that B. pseudomallei and B.
thailandensis are both able to escape the phagolysosome (12, 14, 15), it is not known
how MAb 3VIE5 will affect the intracellular fate of the opsonized bacteria. It is possible
that opsonized bacteria are unable to escape from the phagolysosome, which would
be a desirable characteristic for an antibody-based therapy.
A B. thailandensis E555 GFP macrophage infection assay with imaging flow cytometry
analysis was used to investigate the uptake of opsonized and nonopsonized bacteria. The
MAb 3VIE5 was used in a RAW 264.7 macrophage infection assay at 1mg  ml21, which has
already been shown to be opsonizing, compared to an isotype control antibody and no-
antibody controls. At each time point, cells were harvested and analyzed by imaging flow
cytometry; this generated a percentage of cells infected with B. thailandensis E555 GFP
(Fig. 4A). Statistical analysis of these data indicated that cell association with bacteria
changed over time (P , 0.001; repeated-measures ANOVA) and that the MAb 3VIE5
enhanced association compared to that in the two control groups (P = 0.022 versus no-
antibody and P = 0.020 versus isotype control; Bonferroni’s posttests). An increase in associ-
ation between cell and bacteria with MAb 3VIE5 is to be expected, since we have previ-
ously demonstrated the opsonization ability of this MAb.
It is known that binding of MAb to activating FcgRs increases the number bacteria
associated with lysosomes and that this process can be independent of MAb opsoniza-
tion of the bacteria (30, 31). In order to assess bacterial association with lysosomes, the
lysosome marker lysosomal associated membrane protein 1 (LAMP-1) was detected
with the use of a fluorescently labeled antibody and image analysis software (see Fig.
S2 in the supplemental material). Statistical analysis of these data indicated that LAMP-
1 association with bacteria changed over time (P = 0.003; repeated-measures ANOVA).
We also note that there was some evidence for difference between treatment groups
(P = 0.010; repeated-measures ANOVA); however, the effects were too modest to iden-
tify the nature of which groups might be different from each other (P . 0.05 in all
cases). These data indicate that 3VIE5 MAb opsonization enhanced bacterial uptake;
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however, we could not detect a significant enhancement in maturation of the
phagolysosome.
DISCUSSION
Here, we investigated the ability of monoclonal antibodies to opsonize B. pseudo-
mallei. A macrophage infection assay was chosen as the primary in vitro method to an-
alyze intracellular infection and the effect of antibody opsonization.
Initially, B. thailandensis E555 was used in the development and testing of macro-
phage infection assays before progression to infection assays with B. pseudomallei
FIG 2 B. thailandensis E555 actin tail and multinucleated giant cell (MNGC) formation within RAW 264.7 macrophages. RAW264.7 macrophages were
infected with B. thailandensis E555 enhanced green fluorescent protein (eGFP) and at 20 h postinfection were stained for actin using Alexa Fluor 647
phalloidin and a Hoechst nucleus stain. Images were taken using a confocal laser scanning microscope using 40 (A, B) and 63 (C, D) objectives. Arrows
highlight examples of the bacterial actin tails.
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K96243. B. thailandensis E555 has been shown to be a suitable surrogate for B. pseudo-
mallei K96243 compared to other B. thailandensis strains (32). Data from J774 macro-
phage infection assays show similar intracellular growth profiles for B. thailandensis
E555 and B. pseudomallei K96243 (32), thus confirming the utility of E555 as a surrogate
for B. pseudomallei in macrophage infection studies.
The opsonization ability of the MAbs was consistent across bacterial strain and anal-
ysis technique. The consistent results between the two Burkholderia species tested pro-
vided the opportunity to focus our research on B. thailandensis, which can be handled
FIG 3 Ratio of actin tail fluorescence to bacterial fluorescence. (A) Bacterial actin tail fluorescence to GFP ratio was analyzed at 12 h postinfection using Icy
open-source software. Data consist of 14 data points from 3 separate experimental weeks. **, P = 0.0038; ***, P = 0.0002; ****, P , 0.0001 (two-way analysis
of variance [ANOVA] with Tukey’s multiple-comparison test). (B) Example images used to calculate the actin tail to GFP fluorescence ratio. These images are
a single representation of all the images taken, as the original images are 8,780 by 8,780 pixels. The images shown here are the central image from which
the 5-by-5 tile scan was produced. Bar, 50 mm.
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at a lower level of containment, where a greater spectrum of analysis methods is avail-
able. Imaging flow cytometry combines the high-throughput aspects of standard flow
cytometry (analyzing many cells though a flow cell) with the informative aspects of mi-
croscopy delivering thousands of images of cells. A B. thailandensis E555 strain express-
ing green fluorescent protein (GFP) was used to enable visualization of intracellular
bacteria. Imaging flow cytometry was performed on RAW 264.7 macrophages har-
vested intact from a B. thailandensis E555 GFP infection assay to determine the opsoni-
zation ability of each MAb. The analysis of imaging flow cytometry was based upon a
novel analysis and gating strategy (see Fig. S1 in the supplemental material). This strat-
egy delivered information such as the proportion of cells infected and the relative bac-
terial load.
It has been demonstrated here that imaging flow cytometry is an alternative tech-
nique that can be successfully used to assess antibody opsonization within a macro-
phage infection assay. Imaging flow cytometry offers advantages over CFU analysis,
such as the ability to analyze individual cell infection events, rather than the infection
level of the whole population. It is to be noted that both methodologies have advan-
tages and disadvantages. For example, CFU data are based on viable bacterial count
on a population level, whereas imaging flow cytometry data are unable to distinguish
between live and dead bacterial fluorescence. The comparable data from both meth-
ods increase the confidence in the data set. On a cell-by-cell level, antibody opsoniza-
tion was shown to increase the average number of bacteria per cell, as well as increas-
ing the overall percentage of infected cells in the population. Together, CFU and
imaging flow cytometry analysis provide a robust method for analyzing intracellular
infection levels in cell infection assays.
We observed that MAb opsonization reduced bacterial actin tail formation in vitro. It
is known that B. thailandensis is able to form actin tails, similarly to B. pseudomallei and B.
mallei, and that this is achieved by the conversion of G actin to F actin following bacterial
escape from phagosomes into the cytosol (18, 21, 33). It is believed that bacterial actin-
based motility can cause neighboring cells to contact, allowing the type VI secretory sys-
tem of Burkholderia to cause cell fusion, leading to MNGC formation (24). The mechanism
whereby the anti-capsule MAb 3VIE5 reduced actin tail formation is unknown. It is possi-
ble that MAb opsonization activates the cell, resulting in increased bacterial association
with phagolysosomes and fewer cytosolic bacteria. However, in this study, no significant
increase in association between bacteria and LAMP-1 was observed following antibody
opsonization. Alternatively, opsonized bacteria could still be escaping from phagosomes
FIG 4 Effects of opsonization on RAW 264.7 macrophage association to B. thailandensis (A) and colocalization
between intracellular B. thailandensis and LAMP-1 (B). Data shown are derived from two experiments (both
derived from the mean of two biological replicates) and are shown as a repeated-measures plot. Repeated-
measures ANOVA indicated a time effect in both plots (P , 0.001). Bonferroni’s posttests indicate a difference
in uptake between the 3VIE5 MAb and the control groups (P , 0.05) (A), and the ANOVA test indicated
possible differences in LAMP-1 (P , 0.05) (B); however, these differences were not discernible by posttest.
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but the MAb prevents the bacteria from recruiting and polymerizing host actin in the
cytosol. The mechanism for preventing access to host actin by the MAb is unknown; it
could be as simple as the MAb essentially blocking access to the actin. However, eluci-
dating the exact mechanism requires further research.
Reducing actin tail formation in vitro is a desirable characteristic of a therapeutic
MAb for melioidosis. The ability of the MAb to reduce actin tail formation should, in
theory, reduce the spread of infection between neighboring cells. Cell fusion enables
the bacteria to spread intracellularly between cells, avoiding the extracellular environ-
ment, which may contain antibiotic therapy or host immune responses, such as specific
bacterial antibodies. It is known that neutrophils (34, 35) and NK and CD8 cells (36) are
likely to contribute to removal of bacteria. As an antibody therapy, the anti-CPS MAb
3VIE5 could be particularly useful as a combination therapy with antibiotics, and
potentially with other host-directed compounds, such as autophagy inducers (37). This
could involve utilizing the MAb to prevent bacterial motility within the intracellular
environment, while the secondary component, such as the autophagy inducer or anti-
biotic, promotes bacterial clearance. We have shown that antibody opsonization of
extracellular B. thailandensis can decrease actin tail formation, which in turn could
reduce intracellular bacterial spread, which is a desirable property for a potential
therapeutic.
It is unclear as to whether enhanced uptake by phagocytes would be of therapeutic
value. The intracellular compartment may well provide a growth niche for B. pseudo-
mallei (discussed in the introduction). As such, enhancing uptake may seem like folly.
However, by using opsonization, we are targeting uptake into immune effector cells
that could be activated to kill the bacteria. It is clear, however, that an MAb therapy
alone is not the complete solution to infection. We are therefore combining MAb ther-
apy with antibiotics by developing a proof-of-concept antibody-antibiotic conjugate
(AAC) for melioidosis; at the time of writing, this work is still ongoing. Antibody conju-
gates have the potential to enhance killing by colocalizing antibiotic to bacterium
within the intracellular phagosome environment. This has been demonstrated by
recent developments of an AAC for Staphylococcus aureus and Pseudomonas aerugi-
nosa (38–41). We are currently developing an AAC for melioidosis with the MAb 3VIE5
assessed in this opsonization study. This MAb has been linked to two different antibiot-
ics via a cathepsin-cleavable linker and is currently undergoing in vitro assessment. The
aim of this AAC is to use the opsonization ability of 3VIE5 to deliver antibiotic intracell-
ularly, killing B. pseudomallei bacteria residing within the intracellular environment.
The development of an AAC requires the use of a well-characterized antibody with a
known ability to opsonize and target the bacterium of interest. In this study, the data
we have outlined lays the foundation for the development of an AAC for melioidosis.
In summary, we have shown that a panel of monoclonal antibodies, directed
against the capsule and LPS of B. pseudomallei, are opsonizing in a RAW 264.7 macro-
phage infection assay. Furthermore, an antibody directed against the capsule of B.
pseudomallei has demonstrated the ability to reduce bacterial actin tail formation
within macrophage cells, an important process that the bacterium requires for intracel-
lular motility and, ultimately, for cell-to-cell spread. Imaging flow cytometry has been
demonstrated to be an alternative to the CFU method for analyzing antibody opsoni-
zation of bacteria. In addition, this method offers a greater level of detail for analyzing
antibody opsonization on a single-cell level. A capsule MAb analyzed in this study,
3VIE5, is being developed into an AAC as a proof-of-principle therapeutic for
melioidosis.
MATERIALS ANDMETHODS
Macrophage cell culture. RAW 264.7 macrophages (ECCAC) were routinely cultured in Dulbecco’s
modified Eagle’s medium (DMEM; Gibco) supplemented with 10% inactivated fetal bovine serum
(Gibco) and 2 mM L-glutamine (Gibco). Macrophage cells were cultured within 150-cm2 vented cell cul-
ture flasks (Corning) within a 37°C and 5% carbon dioxide humidified incubator. Cells were regularly pas-
saged by cell scraping and culture into fresh DMEM when approximately 90% confluent; cells were not
used past a passage number of 20.
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Prior to use for an infection assay, macrophages were assessed for viability and counted by trypan
blue (Sigma) cell exclusion using an automated cell counter (Nexcelom). Cells were typically cultured on
24-well cell culture plates (Corning) in DMEM at a concentration of 5  105 cells  ml21 and cultured over-
night within a 37°C, 5% carbon dioxide humidified incubator until cell density reached 1  106 cells  ml21.
Macrophage infection assay. An overnight broth culture of B. thailandensis E555 or B. pseudomallei
K96243 was diluted to an approximate concentration of 1  108 bacteria  ml21 using bacterial optical
density (OD) readings of 0.172 OD at 600 nm (OD600) and 0.4 OD590, respectively. A 10% dilution of this
bacterial suspension was prepared and added to RAW 264.7 macrophages at a multiplicity of infection
(MOI) of 5 for 1 h at 37°C to allow bacterial uptake. Following the incubation period, the culture medium
was removed and replaced with fresh Leibovitz’s L-15 medium containing 1 mg  ml21 kanamycin
(Sigma) and incubated at 37°C to kill any remaining extracellular bacteria. This step was considered the
start of time points to monitor intracellular bacteria. Following a specific incubation period (2 h for op-
sonization studies), the intracellular bacteria were enumerated by cell lysis with distilled water (Gibco)
for a minimum of 10 min, serially diluted, plated onto Luria agar, and incubated at 37°C for 48 h.
Macrophages were also harvested into phosphate-buffered saline (PBS) without lysis for analysis by
imaging flow cytometry; in this case, macrophages were centrifuged at 300  g for 5 min and resus-
pended into 4% paraformaldehyde (Alfa Aesar) prior to analysis. See Fig. 5 for an overview of the assay
design.
Culture of B. thailandensis and B. pseudomallei. B. thailandensis E555 and B. pseudomallei K96243
were routinely cultured in Luria broth and on Luria agar plates. Green and red florescent protein-
expressing strains (pBHR4-groS-eGFP and pBHR4-groS-RFP) of B. thailandensis E555 and B. pseudomallei
K96243 were provided to Dstl by Exeter University, United Kingdom. Fluorescent strains were cultured in
Luria broth and agar supplemented with 50mg  ml21 chloramphenicol to ensure that only plasmid-con-
taining fluorescent protein-expressing bacteria were cultured. Culture of B. thailandensis was performed
within containment level 2 facilities and culture of B. pseudomallei within containment level 3 facilities.
Actin tail staining. RAW 264.7 macrophages on a 35-mm cell culture dish (Corning) were fixed and
permeabilized using a Cytofix/Cytoperm (BD Biosciences) kit following manufacturer’s instructions.
Alexa Fluor 647 phalloidin (Molecular Probes) was added to the RAW macrophages at 5% (vol/vol) and
incubated at room temperature for 30 min. Following incubation, the RAW macrophages were washed
twice with PBS, prior to visualization by confocal microscopy.
LAMP-1 staining. At the specified time point (between 2 and 24 h) postinfection, macrophages
were harvested, transferred to 200 ml fixative-permeabilization buffer (BD Biosciences) and incubated for
FIG 5 Macrophage infection assay. A RAW 264.7 macrophage infection assay was the primary
method to analyze MAb opsonization of B. pseudomallei and B. thailandensis. Antibodies were
incubated with bacteria prior to cell infection to allow for antibody-bacterium binding. Cells were
infected for 1 h, followed by removal and replacement with kanamycin antibiotic medium. At specific
time points, cells were harvested for analysis by imaging flow cytometry and confocal microscopy, or
cells were lysed for bacterial enumeration.
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30 min at room temperature on a roller. Following incubation, the sample volume was increased to 1 ml
with 800 ml of 1 permeabilization-wash buffer (BD Biosciences) and centrifuged for 5 min at 300  g.
Following centrifugation, cells were resuspended into 200 ml permeabilization-wash buffer (BD
Biosciences) containing 3.5 mg  ml21 PE/Dazzle 594 anti-mouse CD107a (LAMP-1) antibody (BioLegend,
UK) and incubated for 1 h at room temperature on a roller. Following incubation, 800 ml of PBS (Gibco)
was added to the samples and centrifuged for 5 min at 300  g. Finally, all cell pellets were resuspended
into 50ml PBS (Gibco) for analysis by imaging flow cytometry.
Confocal microscopy. Confocal microscopy was performed on a confocal laser scanning microscope
(Zeiss). RAW 264.7 macrophages were analyzed on 35-mm cell culture dishes (Corning) using a 20,
40, or 63 oil immersion lens. Hoechst (Sigma) nuclei dye was added to RAW 264.7 macrophage cells
at 2 mg  ml21 to be able to discriminate between individual cells and multinucleated giant cells. Green
fluorescent protein-expressing B. thailandensis E555 (pBHR4-groS-eGFP) was used throughout confocal
microscopy studies.
The bacterial actin tail fluorescence to bacterial GFP ratio was calculated using Icy open-source soft-
ware (http://icy.bioimageanalysis.org/) (29). To include as many cells as possible per image, the confocal
microscope at 20 magnification was set to image a 5 by 5 square tiled image around a chosen field of
view, giving a total image analysis area size of 675 mm2 (see Fig. S3 in the supplemental material). This
process was repeated at multiple other locations on the cell culture dish and replicated across three sep-
arate weeks to generate the final data set.
Imaging flow cytometry. Imaging flow cytometry was performed on an Amnis ImageStream X
mark II imaging flow cytometer. Cell samples were analyzed in a 50-ml volume within an Eppendorf
tube. In total, 10,000 events were collected, consisting of cells gated according to being in focus and sin-
gle cells. Channels 1 (bright field), 2 (GFP), 4 (RFP or LAMP-1), 6 (side scatter), and 9 (bright field) were all
used at full laser power, as standard, during all analysis of B. thailandensis GFP- or B. pseudomallei RFP-
infected RAW macrophages. Magnification was set at 60 for all experiments. Compensation controls
were performed on experiments consisting of more than one fluorescent marker, and the compensation
matrix was then applied during data analysis. Data analysis for bacterial opsonization and LAMP-1
experiments was achieved using IDEAS (Amnis) software (see supplemental material).
Statistical analysis. GraphPad Prism v8 software was used in the preparation of all graphs. For sta-
tistical analysis, bacterial count data and actin ratio data were log10 transformed to better fit the test
requirement for approximate Gaussian distribution equal variance. In all analyses, the test requirements
were assessed using residual plots and quantile-quantile plots of the residuals against the normal distri-
bution. Two-way ANOVA analysis of the actin ratio data was performed using GraphPad Prism v8, and
the three experiments and three conditions were used as the two factors. Three-parameter ANCOVA
analysis of the opsonization in the image stream and CFU data was performed using JASP v13.1 soft-
ware. The three parameters were antibody, pathogen, and dose (log10 transformed and used as a contin-
uous factor). Time course data were analyzed by repeated-measures ANOVA in which treatment and ex-
perimental run were factors. All posttests were performed using Bonferroni’s correction.
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